Semaglutide is a medication that was originally developed to treat type 2 diabetes but has gained popularity for its effectiveness in aiding weight loss
The clinical record sits with the molecules: STEP for semaglutide (NEJM 2021), SURMOUNT for tirzepatide (NEJM 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM 2024)
An X, Yu W, Liu J, Tang D, Yang L, Chen X
Therefore it is not an essential dietary supplement
doi: 10.1111/nph.12304 5 ChengM.-C.KoK.ChangW.-L.KuoW.-C.ChenG.-H.LinT.-P
An epidemiologic study by Apnimed, a clinical-stage pharmaceutical company developing AD109, an oral drug candidate for OSA, demonstrated that most people with OSA60.6%are not obese